Vimarsana
Biggest News Aggregation in the World

Page 8 - Mochida News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mochida. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mochida Today - Breaking & Trending Today

大野将平、2連覇へ「やっと点が線に」 1年延期で見いだした答え - 一般スポーツ,テニス,バスケット,ラグビー,アメフット,格闘技,陸上 [柔道]:朝日新聞デジタル - Vimarsana News

大野将平、2連覇へ「やっと点が線に」 1年延期で見いだした答え - 一般スポーツ,テニス,バスケット,ラグビー,アメフット,格闘技,陸上 [柔道]:朝日新聞デジタル

大野将平、2連覇へ「やっと点が線に」 1年延期で見いだした答え  しかも、コロナ禍で大会は1年延期。自省する時間が増えると、考えを巡らせるようになった。  ヘーシンクの優勝を機に、日本柔道再建を目的に作られたのが講道学舎で、自分がその門下生であったこと。  朝から晩まで柔道漬け。文字どおり、汗と血と涙の日々だった。それでも「普通の青春を送りたかった」とは思わない。心身を削るような10代が、大野将平という柔道å®...

Source: asahi.com
Growing Competition for the World's Most Profitable Drug as Multiple New Adalimumab Biosimilars Launch | Rothwell, Figg, Ernst & Manbeck, P.C. - Vimarsana News

Growing Competition for the World's Most Profitable Drug as Multiple New Adalimumab Biosimilars Launch | Rothwell, Figg, Ernst & Manbeck, P.C.

To embed, copy and paste the code into your website or blog: During the first quarter of 2021, multiple companies launched adalimumab biosimilars as a growing number of biosimilar players marketed their versions of the world’s most profitable drug, Humira ®, which had sales of about $20 billion in 2020. While none have launched thus far, at least eight adalimumab biosimilars are due to launch by the end of 2023 in the United States, where Abbvie secured over $16 billion of its Humira ® sales revenues in 2020. On February 11, 2021, the European Commission (EC) granted marketing authorizati...

Investegate |Idorsia Pharmaceuticals Ltd Announcements | Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2021 – substantial progress made across the pipeline – launch preparations well underway - Vimarsana News

Investegate |Idorsia Pharmaceuticals Ltd Announcements | Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2021 – substantial progress made across the pipeline – launch preparations well underway

131.3 US GAAP revenue of CHF 7 million in the first quarter of 2021 consisted of contract revenue recognized in connection with the collaboration agreements with Neurocrine Biosciences, Inc. (CHF 1 million), Janssen Biotech, Inc. (CHF 3 million), Roche (CHF 2 million) and Mochida Pharmaceutical Co., Ltd (CHF 1 million) compared to a revenue of CHF 5 million in the first quarter of 2020. US GAAP operating expenses in the first quarter of 2021 amounted to CHF 129 million (CHF 116 million in the first quarter of 2020), of which CHF 97 million relates to R&D (CHF 97 million in the first quarter o...

Idorsia announces financial results for the first quarter 2021 – substantial progress made ... - Vimarsana News

Idorsia announces financial results for the first quarter 2021 – substantial progress made ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Idorsia announces financial results for the first quarter 2021 – substantial progress made ... Idorsia Pharmaceuticals LtdApril 22, 2021 GMT Allschwil, Switzerland – April 22, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2021. Business highlights Daridorexant new drug application (NDA) submitted to the US FDA in January 2021 and has been accepted for review Daridorexant marketing authorisation application (MAA) submitted to the European Medicines A...

Source: apnews.com
Seven Seas Acquires 'Daily Report About My Witch Senpai' Manga - Vimarsana News

Seven Seas Acquires 'Daily Report About My Witch Senpai' Manga

Seven Seas Entertainment has another really fun license acquisition with the pickup of the manga series Daily Report About My Witch Senpai. The series comes from Maka Mochida and is known originally as  Majo-senpai Nichijou. The series began in 2018 and wrapped up with two volumes as serialized in Manga Cross magazine for Akita Shoten. Seven Seas will publish the manga series for the first time in North America in print and on digital platforms in single-volume editions. The first volume will be released in January 2022 for $12.99 USA / $16.99 CAN. Plot Concept: Misono is an office drone wi...